UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Reduces Stock Position in Twist Bioscience Co. (NASDAQ:TWST)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lowered its position in shares of Twist Bioscience Co. (NASDAQ:TWST - Free Report) by 3.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 853,675 shares of the company's stock after selling 26,524 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned 1.43% of Twist Bioscience worth $39,670,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently made changes to their positions in the company. Barclays PLC increased its stake in shares of Twist Bioscience by 214.8% during the third quarter. Barclays PLC now owns 153,039 shares of the company's stock worth $6,913,000 after purchasing an additional 104,420 shares during the period. Vanguard Group Inc. grew its position in Twist Bioscience by 3.4% during the fourth quarter. Vanguard Group Inc. now owns 5,807,183 shares of the company's stock worth $269,860,000 after buying an additional 189,791 shares in the last quarter. Wells Fargo & Company MN grew its position in Twist Bioscience by 34.5% during the fourth quarter. Wells Fargo & Company MN now owns 37,886 shares of the company's stock worth $1,761,000 after buying an additional 9,722 shares in the last quarter. KBC Group NV grew its position in Twist Bioscience by 71.4% during the fourth quarter. KBC Group NV now owns 2,942 shares of the company's stock worth $137,000 after buying an additional 1,226 shares in the last quarter. Finally, Teacher Retirement System of Texas grew its position in Twist Bioscience by 18.9% during the fourth quarter. Teacher Retirement System of Texas now owns 17,357 shares of the company's stock worth $807,000 after buying an additional 2,755 shares in the last quarter.

Insider Transactions at Twist Bioscience

In related news, CEO Emily M. Leproust sold 5,042 shares of the stock in a transaction on Monday, May 5th. The stock was sold at an average price of $37.65, for a total value of $189,831.30. Following the transaction, the chief executive officer now owns 655,432 shares of the company's stock, valued at $24,677,014.80. This represents a 0.76% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Patrick John Finn sold 1,877 shares of the company's stock in a transaction dated Wednesday, May 21st. The shares were sold at an average price of $29.75, for a total transaction of $55,840.75. Following the sale, the chief operating officer now owns 240,783 shares of the company's stock, valued at approximately $7,163,294.25. The trade was a 0.77% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 26,850 shares of company stock worth $974,764 in the last 90 days. Insiders own 3.01% of the company's stock.

Wall Street Analyst Weigh In

TWST has been the topic of a number of analyst reports. Scotiabank reissued an "outperform" rating on shares of Twist Bioscience in a research report on Tuesday, February 4th. Guggenheim reissued a "buy" rating and set a $50.00 price target on shares of Twist Bioscience in a research report on Tuesday, May 6th. Barclays reduced their price target on Twist Bioscience from $58.00 to $45.00 and set an "overweight" rating on the stock in a research report on Thursday, April 10th. Robert W. Baird reduced their target price on Twist Bioscience from $54.00 to $44.00 and set an "outperform" rating on the stock in a report on Tuesday, May 6th. Finally, JPMorgan Chase & Co. reduced their target price on Twist Bioscience from $40.00 to $33.00 and set an "underweight" rating on the stock in a report on Tuesday, May 6th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $50.40.

Twist Bioscience Stock Up 2.5%

Twist Bioscience stock traded up $0.73 during midday trading on Friday, reaching $29.62. The stock had a trading volume of 319,936 shares, compared to its average volume of 977,738. Twist Bioscience Co. has a 12 month low of $27.12 and a 12 month high of $60.90. The company has a market capitalization of $1.77 billion, a P/E ratio of -8.84 and a beta of 2.54. The company has a fifty day moving average price of $35.58 and a two-hundred day moving average price of $42.38. The company has a current ratio of 4.96, a quick ratio of 4.62 and a debt-to-equity ratio of 0.03.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last released its quarterly earnings results on Monday, May 5th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.56) by ($0.10). The company had revenue of $92.79 million for the quarter, compared to analyst estimates of $92.00 million. Twist Bioscience had a negative net margin of 59.76% and a negative return on equity of 32.69%. As a group, equities analysts expect that Twist Bioscience Co. will post -2.12 EPS for the current fiscal year.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.